血液循环肿瘤标志物分析 (ALCINA2)

Patient with a locally Advanced tumor or metastatic tumor RH+/HER 2 - , treated by palbociclib

BLOOD SAMPLING

blood sampling time : cycle 1 day 15 and cycle 2 day 15 : one sample (6ml) by time

• 肿瘤取样

Patient with a locally Advanced tumor or metastatic tumor RH+/HER 2 - , treated by ribociclib

BLOOD SAMPLING

blood sampling time : cycle 1 day 15 and cycle 2 day 15 : one sample (6ml) by time

• 肿瘤取样

Patients with histologically proven metastatic bronchial carcinoma eligible for immunotherapy

Blood samples will be collected at four key time points:

• baseline (T1),
• first scan assessment (T2),
• second scan assessment (T3),
• and progression (T4).

Patient with metastatic colorectal adenocarcinoma

Blood samples will be collected before any treatment

Patient with HER2 + metastatic breast cancer, requiring treatment with T-DXd

Blood samples will be collected at four key time points:

• At the inclusion (T1)
• Before the beginning of the treatment (cycle 1 day 1) (T2)
• After the first cycle of T-DXd (cycle 2 day 1) (T3)
• At progression or at the end of the follow-up (after 3 years) (T4)

Patient with grade II, III or IV diffuse glioma

Blood samples will be collected at three key time points:

• At the inclusion (T1)
• For patients starting treatment at the time of inclusion (T2):
• Chemotherapy: 3 months after inclusion,
• Concurrent chemoradiotherapy with Temozolomide: 4-6 weeks after completion of radiotherapy,
• For patients starting treatment at the time of inclusion: at the time of tumor progression if occurring within one year of inclusion, or 12 months after inclusion in the absence of progression (T3).

Patients with non-metastatic colon cancer

Blood samples will be collected before any treatment

Patients with treatment-naive metastatic breast cancer with distant metastases

Blood samples will be collected at five key time points:

• At the inclusion
• At follow-up visit 2 to 6, every 3 months

Patients newly diagnosed with non-metastatic stage II - III early TNBC, requiring neoadjuvant treatment and previously untreated.

Blood samples will be collected at four key time points:

• At the inclusion before the beginning of the treatment (Cycle 1 Day 1)
• After the first cycle of the first chemo-immunotherapy sequence (Cycle 2 Day 1)
• After the first cycle of the second chemotherapy sequence (Cycle 2b Day 1)
• After the end of the whole neo-adjuvant chemo-immunotherapy protocol, before surgery

Patients with well differentiated (WD) liposarcoma, dedifferentiated (DD) liposarcoma or sarcoma other than liposarcoma

Blood samples will be collected before any treatment

Patients with Metastatic bronchial carcinoma activating alterations in EGFR (del 19; L858R) or KRAS G12C

Blood samples will be collected at five key time points:

• At the inclusion (T1)
• At first clinical evaluation (T2): 4th week after start of treatment
• At first scan evaluation (T3a): 8th week after start of treatment
• At the Nth scan evaluation (T3b, c, ...)
• At progression (T4)

Tumor sampling :

• At the inclusion
• At tumor progression

Patient with breast cancer and suspected with leptomeningeal metastases

Blood samples will be collected at several points :

• Inclusion: at the time of suspected leptomeningeal metastases, prior to any specific treatment,
• Every 4 weeks until meningeal progression, or for a maximum of 4 months,
• Then every 3 months beyond 4 months until meningeal progression.

Patients with breast cancer requiring radiotherapy, whatever the tumor stage

Blood samples will be collected before any treatment

Success rate of the tested detection techniques. The success rate of a given detection technique is calculated by the ratio " detection success " / " number of screened patients"

Number of participants with treatment-related neutropenia as assessed by CTCAE v4.03

Number of participants with treatment-related hepatic toxicity as assessed by CTCAE v4.03

Number of CTCs expressing PDL1 at T1

Expression of the MS9 mRNA biomarker

Progression-Free Survival (the primary outcome measure being the HR between CTC+ and CTC- patients, using the HER2+ CTC count at baseline)

Positive predictive value and negative predictive value of the signature to discriminate glioma vs. no glioma

Median number of CTCs 1 month after inclusion

Concordance rate of CTC-AXL measurement (at inclusion) by EPIDROP technique (AXL(-): 0 vs AXL(+): ≥1) and CellSearch technique (AXL(-): 0 vs AXL(+): ≥1)

Response to treatment is defined as a pathological complete response (i.e. no residual invasive tumor in breast and axillary lymph nodes (ypT0ypN0)) after neo-adjuvant therapy.

Sensibility and specificity of circulating MDM2 DNA in circulating vesicles for LPS diagnosis

Number of CTCs expressing HES 1 to T4

Sensitivity of the hepcidin value in the 1st blood sample for the diagnosis of leptomeningeal metastases

The mean RILA at 24h (D1), 48h (D2), 72h (D3) and 96h (D4) will be compared. Equivalences between conditions ((1) 24h and 48h, (2) 24h and 72h, (3) 24h and 96h) will be assessed using Passing & Bablok regression and/or paired t-test. Also, linear regressions between 24h, 48h, 72h and 96h for the same patients will be evaluated in order to determine, if necessary, a conversion formula.